The National Institute for Health and Clinical Excellence has recently published an update of its guidance on medicines for dementia. Denise Taylor describes the history of this guidance and how the changes may impact on practice.

Eribulin mesylate (Halaven; Eisai) has recently received European marketing authorisation for use in locally advanced and metastatic breast cancer. This article describes the evidence for its efficacy and safety.
 

The inappropriate use of antipsychotic drugs in patients with dementia has been of concern for some time. In this article, Jackie Simms describes the results from a review of antipsychotic prescribing in patients with dementia at a GP surgery in the Caerphilly borough of South Wales.

By Caroline Burke, Richard Copeland, Wasim Baqir and Fraser Birrell

An e-training package for those working with intrathecal chemotherapy has been designed and implemented at Norfolk and Norwich University Hospital. This article describes the benefits of using an online training package and how it was developed. By Duncan Macdonald and Matthew Small.

Recent advances in the treatment of prostate cancer were among the array of information presented at last month’s US Hematology Oncology Pharmacy Association conference. Sue Kilby reports.

A recent report from the Academy of Medical Sciences raises a number of concerns about the state of clinical research in the UK. Philip Brown outlines the Academy’s recommendations and asks pharmacists to consider their role in the future of medicines research.